Study design issues in irritable bowel syndrome

Alimentary Pharmacology and Therapeutics

Volumn 19, Issue 1, 2004, Pages 141-142

  Mangel, A W ^a  

^a RTI HEALTH SOLUTIONS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; CARBOLINE DERIVATIVE; GASTROINTESTINAL AGENT; INDOLE DERIVATIVE; PLACEBO; TEGASEROD;

ABDOMINAL PAIN; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FECES ANALYSIS; HEALTH CARE; HUMAN; IRRITABLE COLON; LETTER; PATIENT CARE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; TREATMENT OUTCOME;

CARBOLINES; DOUBLE-BLIND METHOD; GASTROINTESTINAL AGENTS; HUMANS; INDOLES; IRRITABLE BOWEL SYNDROME; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 1642492731     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01816.x     Document Type: Letter

References (9)

1. Corazziari E, Bytzer P, Delvaux M, et al. Consensus report: clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2003; 18: 569-80.
2. Camilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomized, placebo-controlled trial. Lancet 2000; 335: 1035-40.
3. Camilleri M, Chey WY, Mayer EA, et al. Alosetron relieves abdominal pain, and improves abnormal bowel function in female, non-constipated, irritable bowel patients. Arch Intern Med 2001; 161: 1733-40.
4. Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999; 13: 1149-59.
5. Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15: 1655-66.
6. Wolfe SG, Chey WY, Washington MK, et al. Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients. Am J Gastroenterol 2001; 96: 803-11.
7. Mangel AW, Hahn BA, Heath AE, et al. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome. J Int Med Res 1998; 26: 76-81.
8. Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16: 1877-88.
9. Kellow J, Lee OY, Chang FY, et al. An Asia-Pacific, double blind, placebo controlled, randomized study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003; 52: 671-6.